Pharmaceuticals, Biotechnology & Life Sciences

Novavax’s VLP vaccine tech sparks investor buzz as stock hits key averages, yet profits lag—can the biotech company turn breakthrough into gains?

Explore how Eli Lilly’s new UK weight‑loss drug Foundayo and $7B Kelonia deal are reshaping its portfolio, driving stock gains and positioning it for future growth.

Pfizer’s GLP‑1 weight‑loss strategy, spotlighted by the president’s personal transformation video, positions the company to win in China’s booming obesity drug market.

Regeneron’s exec LaRosa buys 45,000 shares, showing confidence yet sparking governance questions—insider moves reveal the biotech giant’s future and investor trust.

Discover how Cytokinetics Inc.’s struggles and innovative muscle‑function therapies are reshaping biotech investment risk.

Explore Canopy Growth’s medical cannabis journey: stock insights, market moves, and future growth prospects in Canada’s pharmaceutical sector.

Explore why Amylyx’s stock surged 79% in August 2026 – analyst upgrades, Avexitide’s Phase‑III trial, and institutional buying drive growth prospects.

Explore ANI Pharmaceuticals’ resilient growth strategy, market performance, and innovation pipeline—why investors see potential amid industry challenges.

Gerresheimer AG discloses European‑wide voting rights, boosting investor transparency and confidence in its life‑science container business.

Explore Ningbo Menovo Pharmaceutical – a mid‑cap Chinese intermediary with high valuation yet low visibility, and why cautious investors stay on the sidelines.